Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes Mellitus
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01219465 |
Recruitment Status : Unknown
Verified September 2010 by Qingdao University.
Recruitment status was: Active, not recruiting
First Posted : October 13, 2010
Last Update Posted : October 13, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetes Mellitus Diabetes Mellitus, Type 1 Mesenchymal Stem Cells Umbilical Cord | Biological: umbilical cord mesenchymal stem cells | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes |
Study Start Date : | September 2010 |
Estimated Primary Completion Date : | September 2012 |
Estimated Study Completion Date : | December 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: umbilical cord mesenchymal stem cells
Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells
|
Biological: umbilical cord mesenchymal stem cells
Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.
Other Name: mesenchymal stem cells |
- C peptide release test [ Time Frame: 3 months ]
- Exogenous insulin dose [ Time Frame: 3 months ]
- blood glucose [ Time Frame: 3 months ]
- glycosylated Hemoglobin A1c [ Time Frame: 3 months ]
- Number of severe and documented hypoglycemic events [ Time Frame: 3 months ]
- Immunologic reconstitution parameters [ Time Frame: 3 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 3 Years to 35 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Confirmed diagnosis of type 1 diabetes by ADA criteria less than 9 weeks.
- Ability to provide written informed consent from patients or Child guardian.
Exclusion Criteria:
- diabetic ketoacidosis.
- evidence of retinopathy at baseline.
- Body Mass Index >30.
- Severe or acute organ damage.
- Infectious diseases, e.g. HIV infection, or hepatitis B or C infection.
- Severe psychiatric disorder.
- Presence of malignancy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01219465
China, Shandong | |
Stem Cell Research Center of Medical School Hospital of Qingdao University | |
Qingdao, Shandong, China, 266003 |
Study Director: | Yangang Wang, MD Phd | The Affiliated Hospital of Qingdao University |
Responsible Party: | Wang, Yangang MD, Stem Cell Research Center of Medical School Hospital of Qingdao University |
ClinicalTrials.gov Identifier: | NCT01219465 |
Other Study ID Numbers: |
MSCT1DM003 |
First Posted: | October 13, 2010 Key Record Dates |
Last Update Posted: | October 13, 2010 |
Last Verified: | September 2010 |
Diabetes Mellitus Diabetes Mellitus, Type 1 mesenchymal stem cells Umbilical cord |
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Autoimmune Diseases Immune System Diseases |